ReviewImmunoTargets and therapy2022
Immunotargets and Therapy for Prurigo Nodularis.
Review in ImmunoTargets and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta-Analysis.International journal of dermatology · 2026Pooled it
- Standardizing Prurigo Control Assessment Globally: Linguistic Validation and Cross-cultural Adaptation of Prurigo Control Test in 18 Languages.Acta dermato-venereologica · 2026Article
- [Chronic prurigo: overview of pathophysiology, diagnosis, and treatment].Dermatologie (Heidelberg, Germany) · 2026Review
- A Conceptual Disease Model of Symptoms and Impacts in Adults with Prurigo Nodularis: A Qualitative and Literature-Informed Study.Dermatology and therapy · 2026Article
- Literature Review: Recent Therapeutic Advances in The Management of Prurigo Nodularis: From Conventional Therapy to Biologics and Targeted Small-Molecule Agents.Clinical, cosmetic and investigational dermatology · 2026Review
- Quantitative Evaluation of Nemolizumab Pharmacokinetics and Efficacy in Prurigo Nodularis: A Population Pharmacokinetics and Model-Based Meta-analysis Approach.Dermatology and therapy · 2025Article
- Th2 mRNA gene expression analysis separates Prurigo nodularis into two immune signature groups.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Observational
- Type 2 Inflammation and Its Role in Dermatologic Diseases.International journal of dermatology · 2025Review
- Dupilumab treatment for prurigo nodularis: a retrospective study of 76 patients.Postepy dermatologii i alergologii · 2025Article
- Successful Treatment of Upadacitinib in Prurigo Nodularis: A Case Report and Review of the Literature.International medical case reports journal · 2025Article
- [Treatment of chronic prurigo: update and perspectives].Dermatologie (Heidelberg, Germany) · 2024Review
- Upadacitinib for prurigo nodularis.JAAD case reports · 2024Article
- Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics.International journal of molecular sciences · 2024Review
- Abrocitinib Monotherapy for Refractory Prurigo Nodularis: Report of Two Successful Cases.Clinical, cosmetic and investigational dermatology · 2024Article
- Targeted Biologic Therapies in Chronic Prurigo: The Evolving Landscape of Chronic Prurigo Treatment.Current pharmaceutical design · 2024Article
- Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments.American journal of clinical dermatology · 2024Review
- Type 2 chronic inflammatory diseases: targets, therapies and unmet needs.Nature reviews. Drug discovery · 2023Review
- Dupilumab Treatment is Not Associated with Increased Risk of Overall Skin Infections [Letter].ImmunoTargets and therapy · 2023Article
- Dermatologic Disease-Directed Targeted Therapy (DDermatology and therapy · 2022Review
- Critical Players and Therapeutic Targets in Chronic Itch.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prurigo nodularis is a chronic inflammatory skin disease consisting of severely pruritic nodules that can be very debilitating for patients. The basis of this skin condition is immunological dysregulation and neural amplification, driven by T-lymphocytes, mast cells, eosinophilic granulocytes, macrophages, and cytokines mediating itchy processes. Further complicating this already taxing diagnosis is the lack of approved treatment and consensus on management; although there are off-label treatments utilized as therapy. Immunomodulators are the cornerstone of treatment for PN, and additional novel therapies targeting key players in the immunological cascade are currently undergoing investigation. In this review, we will highlight targets of the immune cascade and explore current immunomodulating treatments as well as immunotherapies on the horizon for the management of prurigo nodularis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.